0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%

MaxCyte Inc

Healthcare GB MXCT

323.0GBP
-23.0(6.65%)

Last update at 2024-12-19T16:14:00Z

Day Range

321.10340.00
LowHigh

52 Week Range

180.00480.00
LowHigh

Fundamentals

  • Previous Close 346.00
  • Market Cap383.23M
  • Volume29750
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-42.96460M
  • Revenue TTM38.05M
  • Revenue Per Share TTM0.37
  • Gross Profit TTM 39.16M
  • Diluted EPS TTM-0.29

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.57080M -19.08220M -11.81640M -12.89500M -8.86920M
Minority interest - - - - -
Net income -19.78110M -20.12660M -12.64200M -13.57610M -8.86920M
Selling general administrative 25.83M 18.68M 8.39M 6.09M 5.28M
Selling and marketing expenses 18.65M 13.00M 8.33M 7.85M 6.72M
Gross profit 39.16M 30.25M 23.40M 19.12M 14.83M
Reconciled depreciation 2.70M 1.42M 1.05M 0.61M 0.34M
Ebit -27.36050M -18.18860M -11.05670M -12.42000M -8.25460M
Ebitda -20.74600M -16.61390M -9.94310M -11.60040M -7.91060M
Depreciation and amortization 6.61M 1.57M 1.11M 0.82M 0.34M
Non operating income net other - - - - -
Operating income -27.36050M -18.18860M -11.05670M -12.42000M -8.42490M
Other operating expenses 71.62M 52.08M 37.23M 34.04M 25.09M
Interest expense 0.13M 1.04M 0.83M 0.68M 0.61M
Tax provision 0.00000M 0.00000M - - -
Interest income 3.92M 0.15M 0.07M 0.21M 0.17M
Net interest income 3.79M -0.89360M -0.75970M -0.47500M -0.44430M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.78970M 1.04M 0.83M 0.68M -
Total revenue 44.26M 33.89M 26.17M 21.62M 16.67M
Total operating expenses 66.52M 48.44M 34.46M 31.54M 23.25M
Cost of revenue 5.10M 3.65M 2.77M 2.50M 1.84M
Total other income expense net 3.79M -0.89360M -0.75970M -0.47500M -0.44430M
Discontinued operations - - - - -
Net income from continuing ops -23.57080M -19.08220M -11.81640M -12.89500M -8.86920M
Net income applicable to common shares -23.57080M -19.08220M -11.81640M -12.89500M -8.86920M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 286.65M 284.12M 51.78M 29.99M 24.27M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.78M 3.31M 1.00M 0.80M 0.86M
Total liab 32.69M 21.22M 18.55M 16.38M 11.99M
Total stockholder equity 253.97M 262.90M 33.23M 13.60M 12.28M
Deferred long term liab - - - - -
Other current liab 8.03M 6.52M 5.21M 3.55M -0.74170M
Common stock 1.02M 1.01M 0.77M 0.57M 0.51M
Capital stock 1.02M 1.01M 0.77M 0.57M 0.51M
Retained earnings -137.87530M -114.30450M -95.22230M -83.40590M -70.51090M
Other liab 1.32M 0.45M 0.65M 0.34M 0.36M
Good will - - - - -
Other assets 0.81M 0.32M 0.03M - -
Cash 11.06M 47.78M 18.76M 15.21M 11.25M
Cash and equivalents - - - - -
Total current liabilities 15.43M 15.62M 11.61M 9.34M 6.57M
Current deferred revenue 6.71M 6.75M 4.84M 3.19M -
Net debt 5.03M -42.10030M -11.78880M -7.99950M -3.00070M
Short term debt 0.16M 0.53M 0.67M 0.51M 3.19M
Short long term debt - - - - -
Short long term debt total 16.09M 5.68M 6.97M 7.21M 8.25M
Other stockholder equity 390.82M 376.19M 127.67M 96.43M 83.92M
Property plant equipment 33.58M 13.37M 6.49M 5.53M 1.82M
Total current assets 252.27M 270.43M 45.25M 24.45M 22.45M
Long term investments - - - - -
Net tangible assets 253.97M 262.90M 33.23M 13.60M 12.28M
Short term investments 216.27M 207.26M 16.01M 1.50M 3.19M
Net receivables 13.57M 6.88M 5.17M 3.24M 4.90M
Long term debt - - 4.92M 4.90M 5.06M
Inventory 8.58M 5.20M 4.32M 3.70M 2.24M
Accounts payable 0.53M 1.82M 0.89M 2.09M 4.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -2.97570M -2.19810M -1.63650M
Additional paid in capital - - - - -
Common stock total equity - - 0.77M 0.57M 0.51M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.81M 0.32M 0.03M 5.53M 1.82M
Deferred long term asset charges - - - - -
Non current assets total 34.39M 13.69M 6.53M 5.53M 1.82M
Capital lease obligations 16.09M 5.68M 2.05M 2.32M 0.00000M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -24.82330M -191.18360M -14.50590M 1.73M -3.12340M
Change to liabilities -0.18390M 3.99M 2.04M 1.96M 0.00520M
Total cashflows from investing activities -24.82330M -195.01320M -16.57800M 0.45M -3.83310M
Net borrowings - -4.98850M -0.06370M -0.15220M -0.00320M
Total cash from financing activities 2.89M 234.72M 28.90M 12.31M 0.23M
Change to operating activities 7.16M -2.52850M -0.19820M -0.04520M -0.22510M
Net income -23.57080M -19.08220M -11.81640M -12.89500M -8.86920M
Change in cash -36.71770M 29.03M 3.54M 3.96M -14.09370M
Begin period cash flow 47.78M 18.76M 15.21M 11.25M 25.34M
End period cash flow 11.06M 47.78M 18.76M 15.21M 11.25M
Total cash from operating activities -14.78290M -10.67960M -8.78210M -8.80250M -10.48740M
Issuance of capital stock 0.00000M 236.08M 28.57M 12.33M 0.00000M
Depreciation 2.70M 1.42M 1.05M 0.61M 0.34M
Other cashflows from investing activities - - -14.50590M 1.73M -3.12340M
Dividends paid - - - - -
Change to inventory -3.49330M -1.40580M -0.89060M -1.89020M -1.28970M
Change to account receivables -6.69000M -1.70510M -1.81020M 1.59M -1.94790M
Sale purchase of stock - - 28.97M 12.46M 0.23M
Other cashflows from financing activities -24.82330M 3.63M 1.84M 5.09M 0.28M
Change to netincome 9.30M 8.62M 2.84M 1.87M 1.50M
Capital expenditures 18.48M 3.83M 2.07M 1.27M 0.71M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.21090M -1.64470M -0.85820M 1.61M -3.45750M
Stock based compensation 11.75M 7.96M 2.47M 1.75M 1.32M
Other non cash items -2.45150M 0.06M 0.10M 0.08M 0.17M
Free cash flow -33.26010M -14.51380M -10.85420M -10.07380M -11.19710M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MXCT
MaxCyte Inc
-23.0 6.65% 323.00 - - 10.41 2.15 6.75 -6.5763
SN
Smith & Nephew PLC
-3.4 0.35% 977.20 53.70 14.27 1.75 2.26 2.21 13.21
NIOX
NIOX Group PLC
1.00 1.61% 63.00 32.00 20.75 7.92 3.40 7.31 28.40
EKF
EKF Diagnostics Holdings Plc
-1.1 4.38% 24.00 - - 2.40 2.09 2.25 -19.3996
CREO
Creo Medical Group PLC
0.75 4.62% 17.00 - - 4.53 1.91 3.91 -4.68

Reports Covered

Stock Research & News

Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte Inc

9713 Key West Avenue, Rockville, MD, United States, 20850

Key Executives

Name Title Year Born
Mr. Douglas Arthur Doerfler Founder, Pres, CEO & Exec. Director 1956
Mr. Ronald Evan Holtz CPA, Ph.D. Chief Financial Officer 1958
Dr. J. Stark Thompson Ph.D. Consultant 1942
Dr. Cenk Sumen Chief Scientific Officer 1973
Mr. Sean Menarguez Director of Investor Relations NA
Mr. Maher Masoud Exec. VP, Gen. Counsel & Sec. 1975
Mr. Thomas Michael Ross Exec. VP of Global Sales 1961
Dr. James Brady Ph.D. Sr. VP of Technical Applications & Customer Support NA
Dr. Sarah Haecker Meeks Ph.D. Sr. VP of Bus. Devel. NA
Mr. James Lovgren Sr. VP of Global Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions